Encouraging options to high-cost specialty drugs

By Mona Chitre Have you ever wondered why health care spending in the U.S. often exceeds that of other industrialized nations who have health care outcomes similar to ours? It turns out that one reason for this difference is our lack of approved biosimilar medications to compete

Read more